Sandoz withdraws Delysid

Sandoz withdraws Delysid in 1966, closing the unusually open supply arrangement that had helped launch the first wave of psychedelic research. The decision came as controversy gathered around LSD: a compound once distributed to encourage investigation was abruptly removed from circulation, and the research wave it had helped set in motion broke against that withdrawal.

An Unusual Research Policy

The policy grew out of uncertainty about what LSD was and what it might be used for. After Albert Hofmann’s 1943 experience suggested the compound’s possible importance to neurology and psychiatry, Sandoz made Delysid, its brand name for LSD-25, available free to researchers. The company hoped that investigation might identify a commercial application for the drug, whose effects were powerful and difficult to interpret.

Sandoz defined research broadly: therapists who agreed to write up their clinical observations could request LSD. The arrangement therefore did more than supply established scientific investigators. It opened a route for therapeutic practitioners to contribute observations, making the drug’s uses a question for a dispersed body of researchers rather than a single institution.

Withdrawal in 1966

The free-supply policy remained more or less unchanged from 1949 until 1966. That year, alarmed by the controversy surrounding its experimental drug, Sandoz abruptly withdrew Delysid from circulation. The withdrawal was not presented as the resolution of the disputes about LSD’s meaning or application; it was a decisive change in access, ending the arrangement that had supported investigation across those unsettled questions.

The timing gives the event its force. For years, researchers and therapists had been able to pursue different interpretations of LSD through direct study and clinical observation. When Sandoz withdrew the drug, that shared material basis for inquiry disappeared. The account identifies the decision as the point at which the first wave of psychedelic research crashed.

Consequences and Significance

Delysid’s withdrawal marks a reversal in the history of LSD research: the same company that had encouraged broad investigation by supplying the drug free of charge removed it from circulation once controversy became a threat. The policy’s end does not establish that researchers had reached agreement about LSD; rather, it closes the period in which the company’s distribution helped sustain a wide-ranging attempt to find out what the drug could do.

The episode also makes the fragility of that first research wave visible. Its expansion had depended in large part on an unusual corporate decision to provide the compound to a broad class of investigators. In 1966, a similarly consequential corporate decision curtailed that access. The withdrawal thus stands both as a specific response to controversy and as the institutional break that ended the policy behind the first wave.